PubMed HealthSearch

Biomedical subjects

J R Florini

Publications and source records attributed to J R Florini.

At least 19 recordsLinked to original sources

IGF-I regulation of elastogenesis: comparison of aortic and lung cells.

Rat neonatal aortic smooth muscle and pulmonary fibroblast cell cultures were exposed to different amounts of insulin-like growth factor-I (IGF-I, 1-100 ng/ml of medium) for 24 h. Aortic smooth muscle cells exhibited an increase in both steady-state levels of tropoelastin mRNA and soluble elastin with increasing amounts of IGF-I, suggesting that the growth factor is acting by increasing transcription or transcript stability. In contrast, pulmonary fibroblast cultures did not exhibit an elastogenic response to IGF-I because neither the steady-state levels of tropoelastin mRNA nor soluble elastin were affected. Transient transfection of the two cell cultures with a chimeric construct containing 500 bp of the elastin gene 5'-flanking region fused to the chloramphenicol acetyltransferase reporter gene showed that reporter activity was increased threefold in smooth muscle cells treated with IGF-I, whereas activity remains essentially the same in control and growth factor-treated pulmonary fibroblast cells. Receptor binding analyses revealed that both cell types possess the type I IGF-I receptor. Therefore, the lack of an elastogenic response in the lung cells cannot be attributed to lack of the appropriate receptor. These data, obtained in vitro with cell types that are principal producers of lung and aortic elastin, agree with results obtained in vivo. This agreement suggests that the regulation of elastin gene expression varies among cells derived from different tissues and furthermore provides model systems to investigate differential regulation of the elastin gene.

Animals

Paradoxical decrease in myf-5 messenger RNA levels during induction of myogenic differentiation by insulin-like growth factors.

Having previously demonstrated that the insulin-like growth factors (IGFs) induce expression of the myogenin gene, we have now extended our investigation of the induction of myogenesis by the IGFs to a second member of the MyoD family, myf-5. This is the only myogenesis gene other than myogenin expressed early in the differentiation of L6 myoblasts, so its regulation was of particular interest because of our observations on myogenin. In contrast to myogenin, myf-5 mRNA was detectable in proliferating myoblasts, but the steady state levels of myf-5 mRNA fell strikingly for 48 h after the cells were switched to low serum medium containing IGF-II in both murine cell lines and myoblasts cultured from human muscle. In spite of this decrease, translation of myf-5 mRNA appeared essential during the early stages of stimulation of myogenesis by the IGFs; an antisense oligodeoxynucleotide complementary to the first five codons of myf-5 blocked the increase in myogenin mRNA and inhibited morphological (cell fusion) and biochemical (creatine kinase elevation) aspects of myogenesis. We conclude that expression of myf-5 is essential for the initial induction of myogenin by the IGFs, but that subsequent elevation of myogenin expression is independent of myf-5, possibly resulting from autoinduction of the myogenin gene. The functional significance of the dramatic decrease in myf-5 mRNA levels during differentiation is not obvious.

Animals

Induction of gene expression in muscle by the IGFs.

The insulin-like growth factors (IGFs) are usually studied with regard to their general effects on cell growth or differentiation, but the latter actions imply that IGFs may also have effects on expression of specific genes in differentiating target tissues. After 15 years of studies on IGF actions on muscle, we have (with the help of an outstanding group of collaborators) found three specific instances in which IGFs induce expression of a well-characterized gene with at least some degree of specificity. Each of the three genes under consideration plays a major role in the tissue that expresses it, and each of the three kinds of muscle is represented. The genes are (1) skeletal muscle myogenin, which plays a central role in terminal myogenic differentiation of muscle cells to form postmitotic myotubes, (2) smooth muscle aortic elastin, which is of major importance in regulation of blood pressure, and (3) cardiac beta-myosin heavy chain, which is the primary component of the contractile apparatus in older rodents and in all humans. For the first two of these, it has been established that the stimulation is largely if not completely at the level of increased mRNA synthesis, and that reporter gene constructs using 5-untranslated regions of the gene exhibit analogous responses to IGFs, offering the possibility that consensus IGF response elements can be elucidated. The importance of IGFs for skeletal myogenic differentiation is underscored by the observation that myoblasts in 'differentiation' medium exhibit substantial expression of IGF-II if IGFs are not added to the medium. Thus the IGFs play major roles in functions of all three kinds of muscle.+

Animals

"Spontaneous" differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II.

Differentiation of muscle cells to form postmitotic myotubes is usually viewed as being negatively controlled by medium components, sometimes designated "mitogens." However, we have found that a family of mitogenic agents, the insulin-like growth factors (IGFs), are potent stimulators of differentiation in myoblasts which act by inducing expression of the myogenin gene. We show here that this action of the IGFs occurs even when these growth factors are not added to the cell medium; upon transfer to low-serum "differentiation medium," myoblasts begin active expression of the IGF-II gene, at both the mRNA and protein levels. Furthermore, autocrine secretion of IGF-II is essential for the process of terminal differentiation of the cells. These conclusions are based upon four lines of evidence. (1) The rate of spontaneous differentiation in several sublines of myogenic cells correlates with their level of expression of IGF-II. (2) C2 and Sol 8 cells, which secrete high levels of IGF-II, are relatively insensitive to exogenous IGFs, in contrast to L6 lines, which exhibit lower levels of IGF-II gene expression. (3) An antisense oligodeoxyribonucleotide complementary to the first five codons of IGF-II inhibits myogenic differentiation in the absence but not in the presence of exogenous IGF-II. (4) Spontaneous differentiation in response to autocrine IGF-II involves the same mechanism that occurs in cells stimulated by the IGFs, i.e. elevation of expression of the myogenin gene.

Animals

The role of the IGFs in myogenic differentiation.

Of the three families of growth factors/hormones (the FGFs, TGF-betas, and IGFs) that have major effects on the differentiation of skeletal muscle cells, only the IGFs stimulate the process; indeed, the IGFs are the only well-defined agents thus far shown to stimulate myogenesis. All of these agents affect the expression of myogenin, one of the recently discovered family of myogenesis controlling genes, and TGF-beta and FGF inhibit the expression of MyoD1 as well. (L6 cells do not express MyoD1, so we have not looked for an effect of IGFs on it.) At least partly as a result of this action, these agents inhibit or stimulate all aspects of myogenic differentiation--fusion, expression of a set of muscle-specific proteins, and attainment of a postmitotic state--in all tested cell lines and primary muscle cell cultures. It is becoming clear that the myogenic controlling genes are capable of regulating expression of genes for the entire family of muscle specific proteins, so the principal question remaining about actions of these growth factors is the mechanism by which they inhibit or induce expression of the myogenin or MyoD1 genes. In spite of the uncertainty about their interactions, the discovery of the myogenesis controlling genes now provides a much sharper focus for studies on the processes involved in terminal differentiation of skeletal muscle cells. The demonstration that expression of these genes is controlled, both positively and negatively, by specific growth factors that are now readily available opens exciting new possibilities in endocrinology and developmental biology.

Animals

Hormones, growth factors, and myogenic differentiation.

Three families of growth factors/hormones have major effects on the differentiation of skeletal muscle cells. Two (FGF and TGF-beta) are potent inhibitors, and the third (IGF) exhibits a biphasic stimulatory action (but is not inhibitory even at high concentrations). All of these affect the expression of myogenin, one of the recently discovered family of myogenesis controlling genes, and FGF and TGF-beta have been shown to inhibit the expression of MyoD1 (and probably myf-5 and herculin) as well. These agents inhibit or stimulate (respectively) all measured aspects of myogenic differentiation--fusion, expression of a set of muscle-specific genes, and attainment of a postmitotic state--in all cells that are capable of these responses, whether cell lines or primary muscle cell cultures. It now seems clear that the myogenesis controlling genes regulate the entire family of muscle-specific proteins. Therefore the demonstration that expression of these genes is controlled (both positively and negatively) by specific growth factors that are now available at high purity and in useful quantities offers the possibility of understanding myogenic differentiation at a level of molecular detail that is very exciting.

Animals

Insulin-like growth factor-I stimulates terminal myogenic differentiation by induction of myogenin gene expression.

Stimulation of myogenic differentiation by the insulin-like growth factors (IGFs) has been established for many years, but our attempts to elucidate the mechanism of that stimulation have been successful only in eliminating some likely possibilities. The recent discovery of a family of muscle determination genes has opened a new approach to this question, allowing specific focus on those genes that might play central roles in controlling myogenesis. We now report that IGF-I stimulates terminal myogenic differentiation in L6A1 cells by inducing a large increase in expression of the myogenin gene. This conclusion is supported by the following observations. 1) Myogenin mRNA is elevated by IGF-I, with a concentration dependency that parallels the stimulation of differentiation, including a decrease in stimulation at higher concentrations. 2) The time course of elevation of myogenin mRNA is consistent with its acting as an intermediate in the signalling pathway between occupancy of the IGF-I receptor and induction of expression of muscle-specific genes. 3) Inhibitors of myogenesis also inhibit elevation of myogenin mRNA in response to IGF-I. 4) An antisense oligonucleotide to the N-terminus of myogenin prevents the stimulation of differentiation by IGF-I and IGF-II, but has no effect on other actions of IGF-I on myoblasts. MyoD has been reported not to be expressed in L6 cells, and the expression of myf-5 and herculin/myf-6/MRF4 is reportedly low or undetectable. Thus, the stimulation of differentiation by IGF-I can be attributed largely, if not entirely, to increased expression of the myogenin gene. However, the relatively long time period between addition of the IGFs and elevation of myogenin mRNA as well as the inhibition of this process by several inhibitors indicate that increased myogenin mRNA levels are not a simple direct result of occupation of the IGF-I receptor.

Animals

Highly specific inhibition of IGF-I-stimulated differentiation by an antisense oligodeoxyribonucleotide to myogenin mRNA. No effects on other actions of IGF-T.

Myogenin is a member of the recently discovered family of muscle determination genes that have been shown to induce myogenic differentiation in nonmuscle cells and to be closely correlated with terminal differentiation in myoblasts. An antisense oligodeoxyribonucleotide complementary to the first five codons of myogenin blocks the stimulation of terminal myogenic differentiation by insulin-like growth factor I (IGF-I). This effect exhibits a high degree of specificity on two levels; exchanging the positions as few as 2 of the 15 bases in the oligomer abolishes its activity, and none of the other processes stimulated by IGF-I in L6A1 myoblasts are affected by the presence of the oligomer. These processes include cell proliferation as well as incorporation of leucine, uridine, and thymidine into macromolecules. The specificity, ease, and convenience of this approach indicates its potential applicability to studies on actions of other putative controlling genes in other systems.

Animals

Effect of age and IGF-I administration on elastin gene expression in rat aorta.

An age-related decrease in elasticity of arteries has been found in clinical and experimental studies done during the past two decades. We have investigated molecular and endocrine aspects of that decrease by examining the effects of age and insulin-like growth factor-I (IGF-I) on rat aorta elastogenesis. For comparison, pulmonary elastogenesis was examined in the same experimental animals. Different aged groups of male Fischer 344 rats (barrier protected) were implanted with minipumps for a two-week infusion of either 0.1 N acetic acid (vehicle solution) or IGF-I (1.2 mg/kg/day). The DNA content (micrograms DNA/g tissue) decreased with age in aorta but remained fairly constant in lung. Administration of IGF-I increased the aortic DNA content in all but the oldest rats. Conversely, the DNA content of pulmonary tissue was significantly increased in only the youngest animals. The steady-state levels of tropoelastin mRNA decreased dramatically in both aorta and lung with increased age. The decrease was greater in lung than aorta. Administration of IGF-I elevated aortic tropoelastin mRNA steady-state levels, whereas lung tropoelastin mRNA levels were unaffected by IGF-I administration. Aortic tissue synthesized decreased amounts of insoluble elastin with increased age. These results establish a direct relationship between aortic tropoelastin mRNA levels and the synthesis of insoluble elastin in aging. Administration of IGF-I increased aortic elastin synthesis throughout the life span of the rat, although the proportionate increase diminished with age.

Aging

Assay of creatine kinase in microtiter plates using thio-NAD to allow monitoring at 405 nM.

An assay system for creatine kinase using microtiter plates and a plate reader that records absorbancies at 405 nM has been devised. The system is an adaptation of well-established assays that couple creatine kinase with the reactions catalyzed by hexokinase and glucose-6-phosphate dehydrogenase (G6PDH), to give a measurable increase in reduced pyridine nucleotide quantitated by absorbance at 340 nM. Two features of this system are modified for reading at 405 nM: (i) The thioamido derivative of NAD is used because its reduced form exhibits a substantial increase in absorbance at 405 nM, the most commonly available wavelength on microplate readers; and (ii) glucose-6-phosphate dehydrogenase from Leuconostoc mesenteroides is used because it can reduce either NAD or NADP (unlike most other G6PDH enzymes, which require NADP), thus making it unnecessary to use the more expensive thio-NADP. The rate of thio-NAD reduction is linear with enzyme concentration and time over a 20-fold range of concentrations of purified creatine kinase, and the assay also works well with myogenic cells allowed to grow and differentiate in the 96-well plate in which the assay is performed. This system offers considerable savings in cells, time, and material in studies of muscle cell differentiation, for which creatine kinase levels are frequently measured. It also provides a potential method for the convenient and economical measurement of activities of many other enzymes that can be coupled to reduction of thio-NAD.

Animals

Limitations of interpretation of age-related changes in hormone levels: illustration by effects of thyroid hormones on cardiac and skeletal muscle.

Studies on age-related changes in hormone secretion or circulation are frequently interpreted to indicate changes in the functions of target tissues for that hormone. Such interpretations are not necessarily correct. For instance, the levels of thyroid hormone change modestly with age, and responses to this change differ dramatically in cardiac and skeletal muscles. There is a substantial change in myosin isozyme content of the heart, but little or no change in skeletal muscle fiber type distribution in specific pathogen free (SPF) barrier-protected rats. These changes (or lack of them) are reflected in functional differences (or lack of them) in the target tissues. The most obvious difference between the recent studies showing no differences with age in skeletal muscle fiber distribution and previous reports of general decreases with age in content of fast fibers is in animal housing conditions; all of the animals showing an age-related change had been housed in conventional colonies, while those exhibiting little or no change were in SPF barrier-protected facilities.

Aging

Skeletal muscle fiber types and myosin ATPase activity do not change with age or growth hormone administration.

Fischer 344 rats at various ages throughout the life span have been treated with growth hormone, clonidine, and insulin-like growth factor-I to restore circulating somatomedin levels in old animals to levels found in younger rats. The injections were intended to reverse (2-week treatments) or prevent (6-month treatments) deleterious effects of aging on skeletal muscle--specifically the loss of fast fibers during the latter part of the life span. However, measurements of myosin ATPase (and subsequent histochemical fiber type determinations) revealed that the previously reported age-related decrease in ATPase activities and fast fiber content did not occur in barrier-protected specific pathogen free rats or mice. None of the treatments used had a significant effect on the ATPase activity or fiber composition of soleus, extensor digitorum longus, or diaphragm muscles, although parallel determinations in collaborating laboratories verified that the hormones had major effects in other systems. Previously reported decreases with age in ATPase activity of heart muscle were confirmed in our experiments, and these decreases were shown to reflect a change in myosin isozyme composition of the hearts, both at the protein and the mRNA levels of gene expression.

Aging

Effects of growth factors on myogenic differentiation.

It has now been well established that the terminal differentiation of muscle cells in culture is subject to control by hormones and growth factors in the incubation medium. Thus far the most potent and most extensively studied agents are fibroblast growth factor (FGF), the insulinlike growth factors (IGFs), and transforming growth factor-beta (TGF-beta). Independent reports from several laboratories have established that both FGF and TGF-beta are potent inhibitors of differentiation and both appear to act at early stages of commitment to differentiation. Stimulation of differentiation by the IGFs (and by insulin at concentrations in the microgram/ml range) has also been observed and confirmed repeatedly. FGF and IGF are mitogenic for muscle cells, and TGF-beta either has no effect or suppresses cell proliferation, so previous generalizations that mitogens inhibit myogenic differentiation are clearly not valid when results with purified agents in well-defined media are considered. Work with oncogenes and specific toxins is beginning to reveal the mechanisms by which these agents might affect differentiation, and there is reason for optimism that an understanding of the molecular events that control terminal differentiation may be attained in the near future.

Animals

Decrease in transforming growth factor-beta binding and action during differentiation in muscle cells.

We report here the effects of differentiation on the binding and action of transforming growth factor-beta (TGF-beta) in three lines of myogenic cells. In two lines (L6-A1 and C2) which irreversibly differentiate by fusing to form postmitotic myotubes, there is a virtual disappearance of TGF-beta binding sites as differentiation occurs. Analyses of the binding curves by the method of Scatchard indicates that there is little or no change in affinity but a substantial decrease in the number of binding sites. In L6-A1 cells, responsiveness to TGF-beta decreases in parallel to the loss of receptors. The decreases in TGF-beta binding and activity with differentiation are not paralleled by similar changes in another growth factor, insulin-like growth factor-I, which exhibits little change in binding and only a modest decrease in activity as L6-A1 myoblasts differentiate to form myotubes. In a third cell line (BC3H1), which exhibits reversible differentiation without fusion, there is little or no change in TGF-beta binding as the cells differentiate. Comparisons with reported decreases in binding of fibroblast and epidermal growth factors indicates that there are substantial differences in growth factor binding and actions as muscle cells differentiate, but it is not possible to make the simple generalization that differentiation is accompanied by a decrease in binding of all growth factors.

Animals

Actions of transforming growth factor-beta on muscle cells.

It has recently been reported by three laboratories that transforming growth factor-beta (TGF-beta) is a potent and reversible inhibitor of differentiation in myogenic cells. To improve our understanding of this inhibition, we investigated the effects of TGF-beta on several other processes in L6 myoblasts, with emphasis on actions of the insulin-like hormones (which stimulate myoblast differentiation). We found that TGF-beta had no effect on the binding of insulin-like growth factors (IGFs) to their receptors on the cell surface, and it had little or no effect on some actions of the IGFs. There was essentially no change in the suppression of proteolysis or the stimulation of cell proliferation by IGFs when TGF-beta was also added to the medium. However, there was an effect of TGF-beta on another process stimulated by the IGFs; TGF-beta was an equally active and more potent stimulator of amino acid uptake than was IGF-I, and the stimulation was additive beyond the maximal response attained with IGF-I, suggesting that the two act by different mechanisms. TGF-beta had significant effects on myoblast morphology, causing the formation of abundant stress fibers containing cytoplasmic (but not myofibrillar) actin. Addition of TGF-beta at various times after initiation of differentiation demonstrated that TGF-beta inhibits an early process in differentiation. Thus it appears that the interactions of TGF-beta and the IGFs in myoblasts are complex; in some instances the effects of IGFs are inhibited and in others they are mimicked or are unaffected. It is clear that TGF-beta does not act by simply interfering with IGF binding or blocking early steps in its action on myoblasts.

Amino Acids

Hormonal control of muscle growth.

In muscle of whole animals, pituitary growth hormone, the thyroid hormones, and insulin are major growth-promoting hormones, and the glucocorticoids have significant catabolic actions. At the cellular level the primary anabolic hormones for cultured myoblasts are the somatomedins (insulin-like growth factors) and fibroblast growth factor. In these cells physiological concentrations of growth hormone, thyroid hormones, and insulin have no growth-promoting effect; some of the reported actions of insulin probably result from cross-reaction with the somatomedin receptor. Results with purified proteins do not support the view that mitogens block myoblast differentiation; transforming growth factor-beta and interferon are nonmitogenic proteins that inhibit differentiation, insulin-like growth factors are mitogens that stimulate differentiation, and fibroblast growth factor is the only purified mitogen that inhibits differentiation. At least six serum-free media have now been devised for the growth of various kinds of muscle cells under closely defined conditions.

Animals

The type II insulin-like growth factor (IGF) receptor has low affinity for IGF-I analogs: pleiotypic actions of IGFs on myoblasts are apparently mediated by the type I receptor.

We have characterized binding and several actions of the somatomedins [insulin-like growth factors I and II (IGF-I and IGF-II)] on L6 myoblasts. Both IGF-I and IGF-II are potent stimulators of amino acid uptake, cell proliferation, and differentiation; they also suppress protein degradation in these cells. In all measurements, the relative potencies are IGF-I greater than IGF-II greater than insulin. Two recombinant DNA-produced analogs of IGF-I, (Thr59)IGF-I and (N-Met)IGF-I, were as active as native IGF-I in all four assays. However, when 125I-labeled hormones were used for studies of binding to IGF receptors, there was a striking difference between the native and recombinant IGF-I molecules. Both were bound significantly by the type I receptor (a 350K molecule that is dissociated upon sulfhydryl reduction), but the recombinant analogs exhibited little cross-reactivity with the type II receptor (a 220K molecule that is not dissociated by reduction). Thus, the equal activity of native IGF-I and its recombinant DNA-produced analogs coupled with the higher potency of IGF-I (compared to IGF-II) suggest that the type II receptor plays little or no role in the four actions of the somatomedins studied in L6 myoblasts.

Affinity Labels